Interventions-Patients were allocated randomly to receive chemotherapy or only supportive care in a ratio of 2:1 according to performance status, metastatic disease of the liver, and weight loss in the six months before entering the study. Chemotherapy consisted of four week cycles of intravenous leucovorin (200 mg/m2/day) foliowed by 5-fluorouracil (550 mglm2l/day) and cisplatin (20 mglm2/day), each drug being given on the first four days ofthe cycle.
Abstract
Objectives-To compare the length of survival and quality of life in patients given combination chemotherapy in addition to supportive care and in patients given only supportive care.
Design-Randomised study. Setting-Gastrointestinal oncology departments. Patients-40 previously untreated patients with histologically confirmed, measurable colorectal cancer that was locally recurrent or metastatic.
Interventions-Patients were allocated randomly to receive chemotherapy or only supportive care in a ratio of 2:1 according to performance status, metastatic disease of the liver, and weight loss in the six months before entering the study. Chemotherapy consisted of four week cycles of intravenous leucovorin (200 mg/m2/day) foliowed by 5-fluorouracil (550 mglm2l/day) and cisplatin (20 mglm2/day), each drug being given on the first four days ofthe cycle.
Main outcome measures-Length of survival and quality of life score with an optimised functional living index-cancer scale.
Results-Overall survival was significantly longer for patients given chemotherapy (11.0 months) than for those receiving supportive care alone (5 0 months; p=0006). Despite common association of chemotherapy with mild to moderate gastrointestinal symptoms, there was no significant difference between the two groups in global or subgroup quality of life scores. In patients with abnormal scores before treatment, quality of life seemed better in the chemotherapy arm.
Conclusions After fully informed consent was obtained eligible patients were registered by phone at the central statistical office at the University of Vienna. They were allocated randomly to receive supportive care plus chemotherapy (arm A) or supportive care only (arm B) in the ratio of 2:1 (which was based on the assumption of a higher refusal rate in arm B). The assignment was determined by randomisation in blocks of six (as defined by a computer generated random number list) according to performance status (score 0-1 v 2-3), metastatic disease of the liver (assessed by ultrasonography or computed tomography, or both), and weight loss in the six months before entering the study. Supportive care consisted of analgesics, nutritional support, blood transfusions to correct severe anaemia, and psychosocial support. Chemotherapy consisted of leucovorin 200 mg/m2/day by intravenous push followed 30 minutes later by bolus 5-fluorouracil 550 mg/m2/day and cisplatin 20 mg/m'/day, given as a two hour infusion with adequate hydration. An antiemetic regimen comprising dexamethasone, metoclopramide, and lorazepam was routinely used. All chemotherapeutic drugs were given on four consecutive days at four week intervals for a total of six months or until there was evidence of tumour progression.
Quality of life was assessed at entry to the study and every two months with the functional living index for cancer (FLIC). This is a contemporary, well validated, 22 item self report scale developed for repeated use by patients with cancer.9 It provides a single quality of life score based on indices of perceived physical wellbeing, psychological state, and sociability. To counteract difficulties in collection and methodological evaluation of the data'0 we used several refinements of the method, including designation of a central data coordinator and use of a simple 10 point (rather than a continuous) scale. Furthermore, serial results in individual patients at successive time points have been evaluated according to the criteria proposed by Presant et al for assessing palliative response by quality of life (box)." Analyses of changes in quality of life were performed separately for patients whose scores were all normal before treatment and for patients who had at least one score (global score or subgrouping) that was abnormal -that is, more than two standard deviations above results in normal people." Twenty healthy volunteers completed the questionnaire. They had a mean score of 41 (SD 16), and this was used to define a normal value. The duration of palliative response was measured from the time that the response was first observed until a significantly lower score was obtained on two successive measurements. A significant change in score was defined by the 95% confidence interval of the instrument on test-retest analysis assessed during the early part of this trial.
Treatment related toxicity and antitumour responses were assessed periodically in both groups according to World Health Organisation standard criteria."2 The length of time to disease progression and survival time, both calculated from the date of randomisation, were analysed by the Kaplan-Meier product limit method." Differences between groups were evaluated by the logrank test.'4
Results
Between April 1988 and September 1989,40 patients were accrued to the study. Two patients in each treatment arm refused to accept the treatment assigned or participate in the research study, or both. Thus, 36 patients were eligible for analysis of response and toxicity. Of these, 24 were randomised to receive chemotherapy with 5-fluorouracil, leucovorin, and cisplatin (arm A) and 12 to receive no chemotherapy (arm B). During the study two patients randomised to no chemotherapy were treated with 5-fluorouracil alone when symptomatic tumour progression occurred. This decision was made by the patients' doctors; neither patient responded, but both have been included in this analysis.
The pretreatment characteristics of patients in the two groups were similar (table I), although the median time from original diagnosis of colorectal cancer to entry was slightly longer for patients with chemotherapy (8 5 (range 0 to 61) months) than for those who received supportive care alone (5 5 (0 to 22) months). Figure 1 gives the actuarial survival curves for all subjects by randomisation status (including the four patients who refused the assigned treatment). The curves for the two groups were significantly different (p=0 006). Median survivals were 11-0 (4 0 to 37 0) months for patients randomised to chemotherapy and 5 (1-5 to 23) months for those receiving supportive care. The sample size was too small to rule out any differences in survival between patients of different prognostic groups.
Toxicity was common in the chemotherapy group, though symptoms were generally mild to moderate. No Table IV gives the quality of life in the two treatment groups. Overall, there was no difference between the two patient groups, though in patients with abnormal scores before treatment the quality of life seemed better in the chemotherapy group. In the chemotherapy group a transient slight deterioration in quality of life was noticed during treatment with cytotoxic drugs (fig 2) . Thereafter, quality of life improved compared with baseline and with patients in the supportive care group. In the supportive care group supportive drugs resulted in an initial improvement of the quality of life. The improvement was short lived, however, because of disease progression. No significant difference was found between the scores in the two groups. 
Discussion
Many doctors and their patients reject conventional anticancer chemotherapy for disseminated colorectal cancer in favour of unproved altematives because of uncertainty about therapeutic gain and concem about toxic effects. Whether and how much chemotherapy prolongs-survival in advanced colorectal cancer, despite its use for several decades, is not known. 5-Fluorouracil, which was the standard treatment until one or two years ago, was not considered to prolong median survival, although a controlled trial against no chemotherapy has never been done.' Several trials comparing 5-fluorouracil alone with combinations based on biochemical modulation have indicated better objective tumour response with the combination treatment.3 An improvement in survival with combinations of 5-fluorouracil and leucovorin, however, has been observed in only two of seven randomised studies,3'5 and the improvement was only moderate.'5 16 We found that combination chemotherapy with 5-fluorouracil, leucovorin, and cisplatin in patients with metastatic colorectal cancer increased time to progression and length of survival compared with those in patients given only supportive care. Because of the small numbers of patients studied, our findings are only preliminary. Nevertheless, the median increase in survival in patients receiving chemotherapy was six months, during which time, overall quality of life was at least as good as in patients receiving supportive care. In patients with symptomatic disease the quality of life, in fact, seemed better in the chemotherapy arm despite its common association with mild to moderate gastrointestinal side effects.
The advantage of chemotherapy in previously asymptomatic patients might be questioned in view of the side effects and the initial, though only minor and transient, decrease in patients' subjective wellbeing. However, our study was conducted before ondansetron became available, which in our experience would probably have prevented the initial decrease in quality of life in patients receiving cisplatin. Furthermore, the overall gain in time to progression and length of survival was seen in patients both with and without tumour related symptoms. The potential advantage of early treatment in asymptomatic patients with advanced colorectal cancer seems to have been confirmed by a trial from the Nordic Gastrointestinal Tumor Adjuvant Therapy Group.'7 Further advances in the knowledge of prognostic factors should help to identify subgroups of (asymptomatic) patients with a more prolonged clinical course, in whom a wait and see policy seems adequate.
Whether the addition of cisplatin to 5-fluorouracil and leucovorin had any influence on the apparent beneficial effect of palliative chemotherapy in this study remains uncertain. Comparison of objective tumour response rate and median survival time in our chemotherapy group and in phase II and III studies with conventional 5-fluorouracil and leucovorin regimens3 suggest that this is not the case. Severe toxicity was less common in our study, however, and the three drug combination seems to have a better therapeutic index. 8 18 In conclusion, our data indicate that chemotherapy with 5-fluorouracil, leucovorin, and cisplatin improves quality of life in symptomatic patients with metastatic colorectal cancer and prolongs survival. Although the small numbers studied reduces the strength of our results, they support previous, indirect evidence of a beneficial effect of chemotherapy in this disease. In addition, the distribution of characteristics known to affect survival in colorectal cancer'9 was similar in the two study groups.
